Technical Analysis for CLRB - Cellectar Biosciences, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.56 | -3.11% | -0.05 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% |
| Alert | Time |
|---|---|
| Down 1% | about 16 hours ago |
| Possible Inside Day | about 17 hours ago |
| 60 Minute Opening Range Breakdown | about 18 hours ago |
| 2x Volume Pace | about 21 hours ago |
| 1.5x Volume Pace | about 21 hours ago |
Get a Trading Sidekick!
- Earnings date: 11/18/2024
Cellectar Biosciences, Inc. Description
Cellectar Biosciences, Inc., a development stage biopharmaceutical company, develops compounds for the treatment and imaging of cancer. Its proprietary product candidates include I-124-CLR1404, a small-molecule, broad-spectrum, and cancer-targeting positron emission tomography (PET) imaging agent that is in Phase II clinical trial for glioblastoma, as well as in Phase I/II clinical trials for approximately 11 solid tumor indications; and CLR1502, a preclinical, cancer-targeted, and non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. The company also develops I-131-CLR1404, a small-molecule, broad-spectrum, and cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells, as well as is in Phase Ib dose-escalation trial for patients with advanced solid tumors; and CLR1404, a cancer-targeted chemotherapy. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Madison, Wisconsin.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Solid Tumors Imaging Oncology Stem Cell Chemotherapy Radiation Occupational Safety And Health Antineoplastic Drugs Blastoma Glioblastoma Radiation Therapy Targeted Therapy Advanced Solid Tumors Tomography Imaging Agent Positron Emission Tomography Cancer Stem Cell Cancer Stem Cells
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.45 |
| 52 Week Low | 1.55 |
| Average Volume | 313,244 |
| 200-Day Moving Average | 2.75 |
| 50-Day Moving Average | 2.05 |
| 20-Day Moving Average | 1.99 |
| 10-Day Moving Average | 1.94 |
| Average True Range | 0.12 |
| RSI (14) | 19.35 |
| ADX | 20.19 |
| +DI | 9.60 |
| -DI | 31.26 |
| Chandelier Exit (Long, 3 ATRs) | 1.83 |
| Chandelier Exit (Short, 3 ATRs) | 1.92 |
| Upper Bollinger Bands | 2.31 |
| Lower Bollinger Band | 1.67 |
| Percent B (%b) | -0.18 |
| BandWidth | 32.15 |
| MACD Line | -0.09 |
| MACD Signal Line | -0.04 |
| MACD Histogram | -0.0553 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.77 | ||||
| Resistance 3 (R3) | 1.79 | 1.74 | 1.74 | ||
| Resistance 2 (R2) | 1.74 | 1.69 | 1.73 | 1.72 | |
| Resistance 1 (R1) | 1.65 | 1.65 | 1.63 | 1.63 | 1.71 |
| Pivot Point | 1.60 | 1.60 | 1.59 | 1.59 | 1.60 |
| Support 1 (S1) | 1.51 | 1.55 | 1.49 | 1.49 | 1.41 |
| Support 2 (S2) | 1.46 | 1.51 | 1.45 | 1.40 | |
| Support 3 (S3) | 1.37 | 1.46 | 1.39 | ||
| Support 4 (S4) | 1.35 |
